Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01064882 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 104
- Enrollment target
NCT01064882 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 104 participants.
The verdict
NCT01064882, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 104 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of bimatoprost ophthalmic solution 0.005% or 0.015% compared with bimatoprost ophthalmic solution 0.03% once-daily application to the upper eyelid margins in increasing eyelash prominence
Interventions
- DRUG bimatoprost ophthalmic solution 0.03%
- DRUG bimatoprost ophthalmic solution 0.005%
- DRUG bimatoprost ophthalmic solution 0.015%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2010-03 |
| Est. Completion | 2010-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01064882
The ClinicalTrials.gov registry entry for NCT01064882 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which bimatoprost ophthalmic solution 0.03% is the first listed.
NCT01064882 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01064882 about?
NCT01064882 is a clinical study titled "Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence". This study will evaluate the safety and efficacy of bimatoprost ophthalmic solution 0.005% or 0.015% compared with bimatoprost ophthalmic solution 0.03% once-daily application to the upper eyelid margins in increasing eyelash prominence
What is the current status of trial NCT01064882?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2010-03. Estimated completion is 2010-07.
What interventions are being tested in trial NCT01064882?
The interventions under investigation include: bimatoprost ophthalmic solution 0.03% (DRUG), bimatoprost ophthalmic solution 0.005% (DRUG), bimatoprost ophthalmic solution 0.015% (DRUG).
Who is sponsoring clinical trial NCT01064882?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.